| 12122750 |
AT2R antagonists and uses thereof |
Thomas Beauchamp, Zhaogen Chen, Jon Andre Erickson, Maria Cristina Garcia Paredes, Jayana Pankajkumar LINESWALA +3 more |
2024-10-22 |
$5,688,155,000 |
| 8691856 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Philip Arthur Hipskind, Jianke Li, Guoxin Zhu |
2014-04-08 |
$129,322,000 |
| 8609892 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Guoxin Zhu, Jianke Li |
2013-12-17 |
$101,568,000 |
| 8084489 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Mark Donald Chappell, Allie Edward Tripp, Guoxin Zhu |
2011-12-27 |
$102,788,000 |
| 8076374 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Mark Donald Chappell, Philip Arthur Hipskind, Jason Eric Lamar, Guoxin Zhu |
2011-12-13 |
$77,945,000 |
| 7989457 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Mark Donald Chappell, Isabel Cristina Gonzalez Valcarcel, Jason Eric Lamar, Jianke Li, Julie Sue Moyers +3 more |
2011-08-02 |
$31,745,000 |
| 7816557 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Guoxin Zhu |
2010-10-19 |
$51,102,000 |
| 7807702 |
Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses |
Mark Donald Chappell, Philip Arthur Hipskind, Allie Edward Tripp, Guoxin Zhu |
2010-10-05 |
$88,959,000 |
| 7696248 |
Glucagon receptor antagonists, preparation and therapeutic uses |
Jianke Li, Guoxin Zhu |
2010-04-13 |
$64,578,000 |
| 7655641 |
Sulfonamide derivatives as PPAR modulators |
Lynn Stacy Gossett, Jonathan Edward Green, Winton D. Jones, Nathan B. Mantlo, Donald P. Matthews +8 more |
2010-02-02 |
$74,925,000 |
| 7598266 |
Fused heterocyclic derivatives as PPAR modulators |
Nathan B. Mantlo, Guoxin Zhu |
2009-10-06 |
$84,753,000 |
| 7528160 |
Fused heterocyclic derivatives as PPAR modulators |
James Allen Knobelsdorf, Nathan B. Mantlo, Daniel Ray Mayhugh, Xiaodong Wang, Guoxin Zhu +1 more |
2009-05-05 |
$298,927,000 |
| 7405305 |
Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors |
Pamela Albaugh, Jochen Ammenn, Timothy Paul Burkholder, Joshua Clayton, Brian Eugene Cunningham +10 more |
2008-07-29 |
$121,788,000 |
| 7396850 |
Pyrazole derivative as PPAR modulator |
Nathan B. Mantlo, Daniel Ray Mayhugh, Guoxin Zhu |
2008-07-08 |
$91,749,000 |
| 7384965 |
Fused heterocyclic derivatives as PPAR modulators |
Nathan B. Mantlo, Guoxin Zhu |
2008-06-10 |
$65,113,000 |
| 7351728 |
Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists |
Dawn Brooks, Samuel James Dominianni, Alexander Godfrey, Lynn Stacy Gossett, Christopher J. Rito +4 more |
2008-04-01 |
$77,622,000 |
| 7259175 |
Peroxisome proliferator activated receptor modulators |
Nathan B. Mantlo, Guoxin Zhu |
2007-08-21 |
$82,596,000 |
| 7153878 |
Peroxisome proliferator activated receptor modulators |
James Allen Knobelsdorf, Nathan B. Mantlo, Jeffrey Michael Schkeryantz, Quanrong Shen, Alan M. Warshawsky +1 more |
2006-12-26 |
$89,417,000 |
| 6982278 |
Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
Dawn Brooks, Samuel James Dominianni, Alexander Godfrey, Lynn Stacy Gossett, Christopher John Rit +4 more |
2006-01-03 |
$278,769,000 |
| 6620839 |
1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
Yousseff Bennani, Ramin Faghih, Wesley J. Dwight, Anil Vasudevan |
2003-09-16 |
$52,371,000 |
| 6515013 |
1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
Youssef L. Bennani, Ramin Faghih, Wesley J. Dwight, Anil Vasudevan |
2003-02-04 |
$133,023,000 |
